Advanced

Alzheimer's disease: No effect of the CDK5 gene on CSF biomarkers, neuropathology or disease risk

Sjolander, Annica; Andersson, Malin E.; Zetterberg, Henrik; Minthon, Lennart LU ; Bogdanovic, Nenad and Blennow, Kaj (2009) In Molecular Medicine Reports 2(6). p.989-992
Abstract
Cyclin-dependent kinase 5 (cdk5) has been identified as one of the kinases that phosphorylates tau at several Alzheimer's disease (AD)-associated sites. Cdk5 is predominantly expressed in neurons, and has higher activity in AD brains than in non-demented brains. To investigate the effect of the CDK5 gene on AD, we analyzed an SNP of the CDK5 gene (rs2069456) in 347 patients with AD and in 157 controls. CDK5 genetic data was investigated in subgroups in relation to biochemical and neuropathological markers for AD. We found no significant differences in genotype or allele distributions between AD patients and controls. None of the CDK5 gene variants influenced biomarkers for AD.
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
cerebrospinal fluid, apolipoprotein E, beta-amyloid, tau, Alzheimer's disease, cyclin-dependent kinase 5, biomarkers, plaque, tangle
in
Molecular Medicine Reports
volume
2
issue
6
pages
989 - 992
publisher
Spandidos Publications Ltd
external identifiers
  • wos:000270569200018
ISSN
1791-3004
DOI
10.3892/mmr_00000203
language
English
LU publication?
yes
id
3b805870-edc1-4f3e-86a6-b9855b992eee (old id 1507267)
date added to LUP
2009-11-20 15:20:56
date last changed
2016-09-20 04:58:00
@article{3b805870-edc1-4f3e-86a6-b9855b992eee,
  abstract     = {Cyclin-dependent kinase 5 (cdk5) has been identified as one of the kinases that phosphorylates tau at several Alzheimer's disease (AD)-associated sites. Cdk5 is predominantly expressed in neurons, and has higher activity in AD brains than in non-demented brains. To investigate the effect of the CDK5 gene on AD, we analyzed an SNP of the CDK5 gene (rs2069456) in 347 patients with AD and in 157 controls. CDK5 genetic data was investigated in subgroups in relation to biochemical and neuropathological markers for AD. We found no significant differences in genotype or allele distributions between AD patients and controls. None of the CDK5 gene variants influenced biomarkers for AD.},
  author       = {Sjolander, Annica and Andersson, Malin E. and Zetterberg, Henrik and Minthon, Lennart and Bogdanovic, Nenad and Blennow, Kaj},
  issn         = {1791-3004},
  keyword      = {cerebrospinal fluid,apolipoprotein E,beta-amyloid,tau,Alzheimer's disease,cyclin-dependent kinase 5,biomarkers,plaque,tangle},
  language     = {eng},
  number       = {6},
  pages        = {989--992},
  publisher    = {Spandidos Publications Ltd},
  series       = {Molecular Medicine Reports},
  title        = {Alzheimer's disease: No effect of the CDK5 gene on CSF biomarkers, neuropathology or disease risk},
  url          = {http://dx.doi.org/10.3892/mmr_00000203},
  volume       = {2},
  year         = {2009},
}